

# Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction

Cara J. Westmark<sup>1\*</sup>, Maki Kiso<sup>2</sup>, Peter J. Halfmann<sup>3</sup>, Pamela R. Westmark<sup>1</sup>, Yoshihiro Kawaoka<sup>2,3,4</sup>

<sup>1</sup>Department of Neurology, University of Wisconsin, Madison, WI, USA

<sup>2</sup>Department of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

<sup>3</sup>Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA

<sup>4</sup>Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan

## \* Correspondence:


Cara Westmark

westmark@facstaff.wisc.edu

## Supplementary Data

**Supplementary Figure 1:** FMRP is predicted to bind to multiple regions of SARS-CoV-2 RNA. The catRAPID Global Score algorithm with weighted fragmentation predicts multiple FMRP binding sites in both positive (A) and negative (B) sense SARS-CoV-2 RNA. The top 20 interactions are displayed with RNA sequence positions on the x-axis versus interaction score on the y-axis. RNA coordinates are reported relative the NCBI database.

**A** FMRP vs SARS-COV-2 RNA  
Weighted method  
Positive sense (top interactions)



**B** FMRP vs SARS-COV-2 RNA  
Weighted method  
Negative sense (top interactions)

